



## **Lytix Biopharma: Invitation to the Q1 2026 Results Presentation**

**Oslo, Norway, May 15, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) will release its first quarter 2026 financial results on Thursday, May 21th, 2026.**

Join us for a live webcast presentation featuring CEO Øystein Rekdal, CFO Gjest Breistein and CMO Karim Benhadji where they will discuss the results and provide key insights.

**Date:** Thursday, May 21th, 2026

**Time:** 14:00 CET

### **Q&A Session:**

We welcome your questions in advance. Please send them to [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com), and they will be addressed during the Q&A session following the presentation.

### **Webcast Details:**

The presentation and Q&A session will be conducted in English. You can view the live event by registering here: <http://qcnl.tv/p/s6roJjTDW6gVSNwfqof5Rw>

### **Missed the Live Session?**

A recording of the presentation will be available shortly after the event on our financial reports page: <http://www.lytixbiopharma.com/financial-reports>

### **For more information, please contact:**

Gjest Breistein, CFO

+47 952 60 512

[gjest.breistein@lytixbiopharma.com](mailto:gjest.breistein@lytixbiopharma.com)

### **About Lytix:**

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.

For more information, visit [www.lytixbiopharma.com](http://www.lytixbiopharma.com).